All News

handcropped.RA_.jpg

Filgotinib Approved by the EMA for Rheumatoid Arthritis

Jack Cush, MD

On Friday, Gilead and Galapagos announced that the European Commission (EC) has granted marketing authorization for filgotinib (trade name, Jyseleca) their oral, once-daily, JAK1 inhibitor for the treatment of adults with moderate to severe active rheumatoid arthritis (RA) who have resp

Read Article
young.doctors.business.talent

Young Adults are Driving Up COVID-19 Rates

CDC/MMWR

CDC reports that since June 2020 individuals infected with COVID-19 have largely been young adults in the 20-29 year age bracket. Moreover, younger adults appeared to be driving community transmission of COVID-19. 

Read Article
heart.jpg (keep)

DMARDs for Early Rheumatoid Arthritis Have Cardiovascular Benefits

RheumNow

Patients with RA have up to a three-fold increased risk of mortality versus the general population, largely due to an increased incidence of premature CVD, such as atherosclerosis and heart failure.

Read Article
podcast logo

RheumNow Podcast – Lupus Delights (9.18.20)

Jack Cush, MD

Dr Jack Cush reviews the news and journal reports from the past week on RheumNow.com:

Read Article
hip.fracture.jpg

Has the Risk of Hip Fracture Changed over Time?

Jack Cush, MD

Data from the Framingham Heart Study has shown that hip fracture incidence has decreased over time, probably resulting from improved lifestyle changes (less smoking and heavy drinking). 

Read Article
mediterraneansandwich-498379__180.jpg

Mediterranean Diet May Reduce Risk of RA

Jack Cush, MD

Arthritis and Rheumatology reports that a Mediterranean diet (MD) is capable of reducing the high risk of RA among women who have smoked tobacco. The results stem from the E3N Study, a French prospective cohort study that collects dietary data on 98,995 women since 1990. An MD score was derived from standardized questionnaires.

Read Article
14203 early RA cohort looked at adherence to quality standards of care (DMARD use, steroids, early F/U care) and showed adherence lessened need for future hospitalisation (adj HR 0.85); most impact from early DMARDs, worst from steroid use https://t.co/hzICGWyht2

Links:

Dr. John Cush RheumNow ( View Tweet)

Today Janssen announced the FDA has approved golimumab (Simponi Aria) for use in children (> 2yrs) with active Polyarticular Juvenile Idiopathic Arthritis and for pediatric Psoriatic Arthritis https://t.co/ntWJXjEJvc

Links:

Dr. John Cush RheumNow ( View Tweet)

Pfizer announced the FDA has approved tofacitinib (Xeljanz) in children (>2yrs) w/ polyarticular JIA. Approval based on a 225 pt, Phase 3, 18 wk Open Run-in followed by 26-wk randomized, withdrawal study of placebo vs tofa 5 mg qd (or wt based oral soln) https://t.co/9Xo3lriINH

Links:

Dr. John Cush RheumNow ( View Tweet)

Among a 112 patient inflammatory myositis cohort, inclusion body myositis was rare (4 pts) - they tend to be older (67 yrs), male predominance, lower CK (1326-1968), less severe weakness 3.75/5) and poor response to immunosuppressives. https://t.co/VxLOAjstWo

Links:

Dr. John Cush RheumNow ( View Tweet)

Swedish GWAS study of >850,000 individuals shows Genetically predicted BMI (obesity) significantly increases RA riskk, but no correlation of RA risk to waist-to-hip ratios. https://t.co/YkzwjPOVyE

Links:

Dr. John Cush RheumNow ( View Tweet)

Cluster analysis of 168 antiphospholipid pts shows that having arterial thromboses and cardiovascular risk factors was associated with mortality and poorest prognosis in APS. https://t.co/Nb7lZNu4jT

Links:

Dr. John Cush RheumNow ( View Tweet)

Ann Int Med shows again that steroids increase serious infection risk in a dose dependenet manner, but even 5 mg of prednisone or less also gives a small but significant risk of serious infection in RA patients on DMARDs (claims data from Medicare & Optum) https://t.co/bj41SqKP0K

Links:

Dr. John Cush RheumNow ( View Tweet)

Outcomes survey of 229 relapsing polychondritis patients shows that 59% had auricular-onset (AO) and 21% had respiratory -onset (RO), 20% w/ miscellaneous-onset (MO- eye MSK CNS). Poorer prognosis seen in RO & MO subgroups than AO subgroups https://t.co/rzVU42z3EA

Links:

Dr. John Cush RheumNow ( View Tweet)

Metanalysis presented at European Association for the Study of Diabetes (EASD), involving 1,629,854 participants and found #RA was associated with a 23% higher chance of developing T2D, compared to the diabetes risk within the general population https://t.co/Qff7gpzves

Links:

Dr. John Cush RheumNow ( View Tweet)

The RheumNow podcast is up! Lupus delights - Lupus & Diet, Drug induced lupus & brand new biologics for SLE. Good news on immunosuppressives, colchicine and baricitinib in COVID-19 patients. . Watch it here https://t.co/Ymsd3eXN5d or listen to the podcast https://t.co/20FOr3qu3X

Links:

Dr. John Cush RheumNow ( View Tweet)

Uncontrolled retrospective observational study of 31 RA-ILD DMARD refractory pts treated with RTX showed RTX to reverse the PFTs decline (∆%pFVC +8.06%; ∆%pDLCO +12.7%) while reducing median prednisone dose at 1 yr. @32 mos, 74% still on RTX. https://t.co/AVQCm2MpDk

Links:

Dr. John Cush RheumNow ( View Tweet)

Systematic literature review of the incidence of SpA subtypes: psoriatic arthritis overall IR of 9.7 per 100.000 PYs; AS overall IR of 4.8/100kPY, and reactive arthritis overall IR estimate of 3.4/100KPY. Little on undifferentiated spondyloarthritis https://t.co/U8yqk30cWb

Links:

Dr. John Cush RheumNow ( View Tweet)

post hoc analysis of Xrays in tocilizumab poly JIA pts Rx for 2 years in the TENDER and CHERISH trials, shows Tocilizumab may delay radiographic progression in children with sJIA and children with pcJIA with only 3-12% showing xray progression by 2 methods https://t.co/qwREzsaR1L

Links:

Dr. John Cush RheumNow ( View Tweet)

RheumNow Podcast - ACR Reproductive Health Slides (9-11-20) Dr Jack Cush reviews the 2020 ACR Reproductive Health Guidelines This past week we presented an overview to the new 2020 ACR ACR 2020 Reproductive Guidelines - Contraception & Counseling https://t.co/vnPh2EQZ0a https://t.co/T4y69DYIH7

Links:

Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×